Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients. Methods: We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan’s cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray’s cumulative incidence and Cox subdistribution hazards models to analyze HCC development. Results: Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not using metformin had a 51% increased risk of HCC compared to non-DM patients, while HLP patients on statins had a 50% reduced risk compared to those without HLP. The 5-year HCC incidence was significantly higher for metformin non-users (16.5%) versus non-DM patients (11.3%; adjusted sub-distribution hazard ratio [aSHR]=1.51; P=0.007) and metformin users (3.1%; aSHR=1.59; P=0.022). Statin use in HLP patients correlated with a lower HCC risk (3.8%) compared to non-HLP patients (12.5%; aSHR=0.50; P<0.001). Notably, the increased HCC risk associated with non-use of metformin was primarily seen in non-cirrhotic patients, whereas statins decreased HCC risk in both cirrhotic and non-cirrhotic patients. Conclusions: Metformin and statins may have a chemopreventive effect against HCC in CHC patients who failed antiviral therapy. These results support the need for personalized preventive strategies in managing HCC risk.
Abstract
Background/Aims: Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients. Methods: We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan’s cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray’s cumulative incidence and Cox subdistribution hazards models to analyze HCC development. Results: Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not using metformin had a 51% increased risk of HCC compared to non-DM patients, while HLP patients on statins had a 50% reduced risk compared to those without HLP. The 5-year HCC incidence was significantly higher for metformin non-users (16.5%) versus non-DM patients (11.3%; adjusted sub-distribution hazard ratio [aSHR]=1.51; P=0.007) and metformin users (3.1%; aSHR=1.59; P=0.022). Statin use in HLP patients correlated with a lower HCC risk (3.8%) compared to non-HLP patients (12.5%; aSHR=0.50; P<0.001). Notably, the increased HCC risk associated with non-use of metformin was primarily seen in non-cirrhotic patients, whereas statins decreased HCC risk in both cirrhotic and non-cirrhotic patients. Conclusions: Metformin and statins may have a chemopreventive effect against HCC in CHC patients who failed antiviral therapy. These results support the need for personalized preventive strategies in managing HCC risk.
참고문헌 (40)
- Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the Global Burden of Disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- Yu ML, "Path from the discovery to the elimination of hepatitis C virus : honoring the winners of the Nobel Prize in Physiology or Medicine 2020", Kaohsiung J Med Sci, 37, pp.7~11 (2021)
- Hsu WF, "Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications(Taiwanese chronic hepatitis C cohort)", J Gastroenterol Hepatol, 36, pp.2884~2892 (2021)
- Yeh ML, "Characteristics and survival outcomes of hepatocellular carcinoma developed after HCV SVR", Cancers(Basel), 13, pp.3455~ (2021)
- Beste LA, "Hepatitis C-related hepatocellular carcinoma incidence in the veterans health administration after introduction of direct-acting antivirals", JAMA, 324, pp.1003~1005 (2020)
- Huang CF, "Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy", Medicine(Baltimore), 95, pp.e4157~ (2016)
- Huang CF, "Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals", Hepatol Int, 12, pp.544~551 (2018)
- Ciancio A, "Long-term follow-up of diabetic and nondiabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents", Liver Int, 41, pp.276~287 (2021)
- Wang HW, "Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy : a nationwide real-world Taiwanese cohort study", Am J Cancer Res, 12, pp.3164~3174 (2022)
- Huang JF, "Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection", Am J Gastroenterol, 103, pp.1933~1940 (2008)
- Davila JA, "Diabetes increases the risk of hepatocellular carcinoma in the United States : a population based case control study", Gut, 54, pp.533~539 (2005)
- Cunha V, "Metformin in the prevention of hepatocellular carcinoma in diabetic patients : a systematic review", Ann Hepatol, 19, pp.232~237 (2020)
- Tsai PC, "Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan", J Hepatol, 78, pp.281~292 (2023)
- Simon TG, "Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus : results from ERCHIVES", Hepatology, 64, pp.47~57 (2016)
- Scheuer PJ, "Classification of chronic viral hepatitis : a need for reassessment", J Hepatol, 13, pp.372~374 (1991)
- Castéra L, "Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C", Gastroenterology, 128, pp.343~350 (2005)
- Lin YH, "The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases", Kaohsiung J Med Sci, 32, pp.362~366 (2016)
- Wang CC, "Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase", platelet ratio index in chronic hepatitis C patients, 2015, pp.114, 923~928
- Gray RJ, "A class of K-sample tests for comparing the cumulative incidence of a competing risk", Ann Stat, 16, pp.1141~1154 (1988)
- Fine JP, "A proportional hazards model for the subdistribution of a competing risk", J Am Stat Assoc, 94, pp.496~509 (1999)
- Dai CY, "Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels : a community-based study", J Hepatol, 49, pp.9~16 (2008)
- Dai CY, "Chronic hepatitis C infection is associated with insulin resistance and lipid profiles", J Gastroenterol Hepatol, 30, pp.879~884 (2015)
- Huang CF, "Cure or curd : modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication", Kaohsiung J Med Sci, 36, pp.920~928 (2020)
- Jeong GH, "Effect of statin on cancer incidence : an umbrella systematic review and meta-analysis", J Clin Med, 8, pp.819~ (2019)
- El-Serag HB, "Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes", Gastroenterology, 136, pp.1601~1608 (2009)
- Butt AA, "Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons : results from ERCHIVES", Hepatology, 62, pp.365~374 (2015)
- Tsan YT, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection", J Clin Oncol, 31, pp.1514~1521 (2013)
- Chen HP, "Metformin decreases hepatocellular carcinoma risk in a dosedependent manner : population-based and in vitro studies", Gut, 62, pp.606~615 (2013)
- Jiang Z, "Metformin inhibits tumorigenesis in HBVinduced hepatocellular carcinoma by suppressing HULC overexpression caused by HBX", J Cell Biochem, 119, pp.4482~4495 (2018)
- Babcook MA, "Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer", Mol Cancer Ther, 13, pp.2288~2302 (2014)
- Babcook MA, "Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1-and Ripk3-dependent necrosis in C4-2B osseous metastatic castrationresistant prostate cancer cells", Cell Death Dis, 5, pp.e1536~ (2014)
- Freeman AJ, "Estimating progression to cirrhosis in chronic hepatitis C virus infection", Hepatology, 34(4 Pt 1), pp.809~816 (2001)
- El-Serag HB, "Hepatocellular carcinoma : epidemiology and molecular carcinogenesis", Gastroenterology, 132, pp.2557~2576 (2007)
- Yu ML, "Time-Degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients : a model for prioritization of treatment", Clin Cancer Res, 23, pp.1690~1697 (2017)
- El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma", Gastroenterology, 126, pp.460~468 (2004)
- Cramp ME, "HBV + HCV = HCC?", Gut, 45, pp.168~169 (1999)
- Yu ML, "A sustained virological response to interferon or interferon", ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C : a nationwide, multicentre study in Taiwan, 2006, pp.11, 985~994
- Lu MY, "Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients : A nationwide hepatitis C virus registry program", Clin Mol Hepatol, 30, pp.64~79 (2024)
- Yu ML, "An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan", Hepatol Int, 18, pp.461~475 (2024)
- Hsu PY, "Comedications and potential drug-drug interactions with directacting antivirals in hepatitis C patients on hemodialysis", Clin Mol Hepatol, 27, pp.186~196 (2021)